Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of GKL-006 injection in advanced pancreatic cancer
CTR20263822Phase 2Active
- Sponsor
- Gene-Qi-Ming
- Start
- Oct 2026
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GKL-006 in pancreatic adenocarcinoma (PDAC), sponsored by Gene-Qi-Ming. Started Oct 2026; status: active.
02
Drugs
GKL-006
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20263822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263822.